MedPath

Efficacy of universal prophylaxis with oral ivermectin for strongyloidiasis in patients administered high-dose corticosteroids

Completed
Conditions
Strongyloidiasis in patients who administered high-dose corticosteroids.
S. stercoralis, strongyloidiasis, ivermectin, prophylaxis, corticosteroids
Registration Number
TCTR20221115001
Lead Sponsor
/A
Brief Summary

During follow-up period, S. stercoralis was detected in three patients, two in prophylaxis group and one in definite therapy group which had no statistically significant difference (p-value 1.000). No case of disseminated strongyloidiasis was found. The expense to perform universal prophylaxis strategy was higher than the definite therapy significantly (562.80 vs 254.37 THB/case, p-value .001).

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
250
Inclusion Criteria

18 years of age or older
Admitted to Khon Kaen University Srinagarind Hospital between January 2015 and June 2019
Received at least 0.5 mg/kg/day of prednisolone or equivalent for at least 14 consecutive days

Exclusion Criteria

Had received ivermectin or other drugs for S. stercoralis such as albendazole within 30 days before enrollment
Had evidence of strongyloidiasis but did not receive treatment within seven days
Allergic to ivermectin
Medical records were missing important information

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of S. stercoralis cases detected at 12 months after high dose steroid initiation Fecal examination
Secondary Outcome Measures
NameTimeMethod
Cost at 12 months after high dose steroid initiation Thai Baht
© Copyright 2025. All Rights Reserved by MedPath